A quarter of patients with cirrhosis caused by metabolic dysfunction-associated steatotic liver disease present before the age of 50 with distinct inherited genetic risk factors and type 2 diabetes, according to data from a prospective multicenter study published in Clinical Gastroenterology and Hepatology. Researchers found that younger adults developing this advanced liver disease show a unique susceptibility profile, meaning standard screening approaches that rely on age may miss crucial diagnoses.
Early-Onset MASLD Cirrhosis Driven by Genetics and Diabetes
Data from the national Nonalcoholic Steatohepatitis Clinical Research Network evaluated 2,395 patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease, known as MASLD. Among them, 9.8% had cirrhosis. The cutoff for early-onset MASLD cirrhosis fell in the lowest quartile of age at less than 50 years old, encompassing 53 participants, while 181 participants presented at 50 or older. Loomba noted in a press release that younger adults developing cirrhosis from this condition are not simply experiencing the same disease earlier. Instead, they exhibit a unique combination of genetic susceptibility and metabolic risk factors accelerating progression to advanced liver disease.
In multivariable models adjusting for demographic and metabolic factors, researchers established that a high genetic risk score and type 2 diabetes were independently associated with early-onset MASLD cirrhosis. Specifically, a high genetic risk score yielded an odds ratio of 2.33, while type 2 diabetes carried an odds ratio of 3.74. Furthermore, the prevalence of cirrhosis increased for patients with both low and high genetic risk scores if they also had type 2 diabetes, jumping from 2.0% to 9.5% and from 6.2% to 10.7%, respectively. Genetic risk scores were calculated by summing alleles across three single-nucleotide polymorphisms—PNPLA3, HSD17B13, and TM6SF2—selected for their known association with cirrhosis across multiple studies.
Did you know? Only 6% of study participants reported alcohol consumption two or more times per month, with no discernible difference between the early-onset and non-early MASLD cirrhosis groups.
Why Standard Fibrosis Screening Tools Miss Younger Patients
Standard clinical screening relies heavily on age-dependent first-line liver fibrosis tools like the Fibrosis-4, or FIB-4, index. However, because these tools factor age directly into their calculations, they miss nearly a third of patients with early-onset MASLD cirrhosis, according to co-author Veeral Ajmera of the University of California San Diego. Loomba and his team emphasized that relying solely on these conventional metrics can leave high-risk younger adults undiagnosed.
To capture these overlooked cases, researchers evaluated alternative thresholds. Within their cohort, a FIB-4 cut-point of 1.0 identified 82.7% of cases. The study authors suggested that this supports direct referral for fibrosis assessment in these patients irrespective of traditional FIB-4 scores. When comparing participants under age 50, those with cirrhosis more frequently presented with a body mass index of at least 35, higher alkaline phosphatase levels, and lower alanine aminotransferase levels than their non-cirrhotic counterparts.
Frequently Asked Questions
What defines early-onset MASLD cirrhosis?
Early-onset metabolic dysfunction-associated steatotic liver disease cirrhosis is defined as presenting before the age of 50, which marked the lowest quartile of age in the study cohort.
What factors drive early-onset MASLD cirrhosis?
According to the study published in Clinical Gastroenterology and Hepatology, high genetic risk scores involving specific single-nucleotide polymorphisms and type 2 diabetes are independently associated with the condition.
Why do standard screening tools miss early-onset cases?
First-line tools like the FIB-4 index incorporate age into their formulas, causing them to miss a substantial portion of younger adults who are developing advanced liver disease.
Take Action: Stay informed on the latest clinical research by exploring our gastroenterology news section or subscribing to our weekly clinical updates newsletter.
Worth a look